Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Fourth-Line Ripretinib Elicits Significant Responses in Advanced GIST

October 22nd 2020

César Serrano-García, MD, PhD, highlights ripretinib and the meaningful benefit it provides as a fourth- and later-line therapy in patients with advanced gastrointestinal stromal tumor who harbor KIT or PDGFRA mutations.

Dr. Abraham on Remaining Questions With Pexidartinib in TGCT

October 21st 2020

John A. Abraham, MD, FACS, discusses remaining questions with pexidartinib in tenosynovial giant cell tumor.

Dr. D’Amato on the Limitations of Liquid Biopsy in Sarcoma

October 21st 2020

Gina Z. D'Amato, MD, discusses the limitations of liquid biopsy in sarcoma.

Dr. Maki on the Utility of IDH1/2 Inhibitors in Chondrosarcoma

October 21st 2020

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the utility of IDH1/2 inhibitors in chondrosarcoma.

Dr. Abraham on the Clinical Utility of Pexidartinib in TGCT

October 20th 2020

John A. Abraham, MD, FACS, discusses the clinical utility of pexidartinib in tenosynovial giant cell tumor.

Ripretinib Continues to Showcase Clinically Meaningful Benefit, Safety in Advanced GIST

October 19th 2020

Ripretinib continues to show clinically meaningful benefit with an acceptable safety profile when used as a fourth- or later-line treatment for patients with advanced gastrointestinal stromal tumor.

Dr. Maki on the Utility of Tazemetostat in Epithelioid Sarcoma

October 19th 2020

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the utility of tazemetostat in epithelioid sarcoma.

Pediatric Osteosarcoma Harbors a High Incidence of Pathogenic TP53 Variants

October 19th 2020

TP53 was found to be the only gene with a germline de novo pathogenic or likely pathogenic variant in pediatric patients with osteosarcoma.

Dr. Pautier on Results of the LMS-02 Trial in Uterine and Soft Tissue Sarcomas

October 16th 2020

Patricia Pautier, MD, discusses the results of the phase 2 LMS-02 trial with doxorubicin and trabectedin in uterine and soft tissue leiomyosarcoma.

Dr. Schwartz on Future Research Efforts in Sarcoma

October 15th 2020

Gary K. Schwartz, MD, discusses future research efforts in the field of sarcoma.

Dr. Maki on the Potential Utility of Immunotherapy in Sarcoma

October 14th 2020

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the potential utility of immunotherapy in sarcoma.

Dr. Tseng on the Significance of the TARPSWG Analysis in Retroperitoneal Sarcoma

October 9th 2020

William W. Tseng, MD, discusses the significance of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group analysis in retroperitoneal sarcoma.

Dr. D’Amato on the Diminishing Role of Chemotherapy in Sarcoma

October 9th 2020

Gina Z. D'Amato, MD, discusses the diminishing role of chemotherapy in sarcoma.

Lancet Oncology Data Reinforce Regulatory Approvals of Tazemetostat in Sarcoma, Follicular Lymphoma

October 9th 2020

Tazemetostat demonstrated durable responses and sustained safety in patients with epithelioid sarcoma and relapsed/refractory follicular lymphoma.

Dr. Maki on the Evolving Treatment Landscape in Soft Tissue Sarcoma

October 8th 2020

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the evolving treatment landscape of soft tissue sarcoma.

Dr. Pautier on Challenges With Drug Development in Leiomyosarcoma

October 6th 2020

Patricia Pautier, MD, discusses limitations in leiomyosarcoma.

Dr. Tseng on the Rationale for the TARPSWG Analysis in Retroperitoneal Sarcoma

October 5th 2020

William W. Tseng, MD, discusses the rationale for the Transatlantic Australasian Retroperitoneal Sarcoma Working Group analysis in retroperitoneal sarcoma.

High-Grade Surface Osteosarcoma Exhibits Poor Oncologic Outcomes

October 5th 2020

The survival outcomes of patients with high-grade surface osteosarcoma is poor, despite the use of contemporary treatment with surgery and chemotherapy.

Dr. Abraham on the Surgical Management of TGCT

October 2nd 2020

John A. Abraham, MD, FACS, discusses the surgical management of patients with tenosynovial giant cell tumor.

Dr. Zalcberg on the Management of Patients With GIST

October 1st 2020

John Zalcberg, PhD, OAM, discusses the management of patients with gastrointestinal stromal tumor.